# HSV-2 gE2/gI2 are immune evasion molecules that bind IgG Fc to inhibit antibody-dependent cellular cytotoxicity

## TL;DR

This study shows that HSV-2 proteins gE2 and gI2 block a key immune response called ADCC by binding to antibodies, and blocking this interaction can restore immune function.

## Contribution

The study identifies gE2/gI2 as immune evasion molecules that inhibit ADCC by binding IgG Fc and shows that blocking this interaction enhances ADCC.

## Key findings

- Antibodies to gC2/gD2/gE2 mediate ADCC against HSV-2.
- gE2/gI2 inhibits ADCC by binding IgG Fc.
- Blocking gE2's IgG Fc binding domain prevents ADCC inhibition.

## Abstract

HSV-2 glycoproteins C, D, and E (gC2/gD2/gE2) are immunogens included in an experimental HSV-2 vaccine. We evaluated whether these antigens serve as targets for antibody-dependent cellular cytotoxicity (ADCC).

We transiently transfected HEK cells with gC2/gD2/gE2 DNA, added HSV-2 seropositive human convalescent sera (HCS), and measured surface CD107a expression on human NK cells by flow cytometry.

We demonstrated that antibodies to gC2/gD2/gE2 mediate ADCC. HSV-2 gE and gI form a complex that binds IgG Fc. We next determined whether gE2/gI2 inhibits ADCC, a crucial function mediated by the IgG Fc, by comparing ADCC titers when HCS were added to cells transfected with gD2, gI2, and a gE2 mutant (gE2MUT) unable to bind IgG Fc or gD2, gI2, and gE2 wild-type (gE2WT). ADCC titers increased by 6.5-fold when cells were transfected with the gE2MUT versus gE2WT (P=0.01). We then spiked HCS with a gE2 mAb that blocks IgG Fc binding, or with a gE2 mAb that does not block IgG Fc binding. The blocking mAb significantly increased titers (P<0.0001), whereas a non-blocking gE2 mAb had no effect.

We conclude that antibodies to gC2/gD2/gE2 are targets of ADCC, that gE2/gI2 inhibits ADCC, and that an mAb that targets the gE2 IgG Fc binding domain can prevent this inhibition.